Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Income towards Common Stockholders (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Net Income towards Common Stockholders for 4 consecutive years, with -$66.2 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 40.57% to -$66.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$197.5 million through Dec 2025, up 16.21% year-over-year, with the annual reading at -$197.5 million for FY2025, 16.21% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$66.2 million at Centessa Pharmaceuticals, down from -$54.9 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$24.9 million in Q2 2023, with the low at -$111.3 million in Q4 2024.
  • Average Net Income towards Common Stockholders over 4 years is -$50.0 million, with a median of -$47.1 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders surged 61.51% in 2023, then plummeted 202.22% in 2024.
  • Over 4 years, Net Income towards Common Stockholders stood at -$43.2 million in 2022, then rose by 14.68% to -$36.8 million in 2023, then tumbled by 202.22% to -$111.3 million in 2024, then skyrocketed by 40.57% to -$66.2 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$66.2 million, -$54.9 million, and -$50.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.